Global Drug Eluting Stents Market 2018-2024
  • ID: 1330
  • July 25, 2018
  • 110 pages
  • Infoholic Research

Global Drug-eluting Stents Market – Drivers, Restraints, Opportunities, Trends, and Forecast: 2018–2024
Overview: Drug-eluting stents refer to the metal stents that have a coating of drugs such as paclitaxel, everolimus, and also antiproliferative drugs to widen the narrowed blood vessel. The first-generation DES has raised safety issues due to a higher incidence of stent thrombosis, which has further given rise to biodegradable DES to provide better treatment. The ability to release an antiproliferative drug that avoids neointimal proliferation, which reduces the incidence of stent restenosis and prevent the need of restenting. These benefits contributed to the domination of DES in 2016. However, thrombosis, along with vasomotion, is the major issue that needs to be addressed in the DES market. Drug-eluting stents find importance in cardiovascular complications as it is a minimally invasive surgical procedure, broadens the constricted blood vessels, and is useful in prolonging the life of the patient.
Increasing prevalence of cardiovascular diseases, rising aging population, growing acceptance for minimally invasive endovascular surgeries, and good reimbursement facilities are few of the factors driving the growth of the DES market. Increasing healthcare spending, rise in the number of outpatient procedures, and market expansion opportunities in emerging nations are providing an opportunity for the growth of the market. However, alternatives for drug-eluting stents, lack of skilled healthcare professionals, and stringent regulatory approval process are hampering the growth of the market.
Market Analysis: The “global drug-eluting stents market” is estimated to witness a CAGR of 5.4% during the forecast period 2018–2024. The market is analyzed based on four segments – coating type, applications, end-users, and regions.
Regional Analysis: The regions covered in the report are North America, Europe, Asia Pacific, and Rest of the World (RoW). Europe accounts for the largest share of the drug-eluting stents market, followed by Europe, Asia Pacific, and Rest of the World. More than 60% of the market is occupied by Europe, with Germany being the major contributor to the market growth.
Coating Type Analysis: Based on the type of coating, the market is segmented into polymer-based coating and polymer-free coating drug-eluting stents. Non-biodegradable and biodegradable polymer are the two types of polymer-based coatings. Microporous surface, microstructured surface, slotted tubular surface, and nanoporous surface are the types of polymer-free coating.
Application Analysis: Based on applications, the market is segmented into coronary artery disease and peripheral artery disease. Approximately 90% of all percutaneous interventional surgeries use a coronary stent of all stenting procedures is done with drug-eluting stents (DES). Therefore, the majority of the market is occupied by coronary arterial intervention.
End-users Analysis: The major end-users in the drug eluting stents market are cardiology centers, ambulatory surgery centers (ASCs), and hospitals. The advantages such as availability of surgery specialists, reduced hospital stay duration, and less charge of surgery have made ambulatory surgical centers the most preferred mode for the treatment. This has made them the largest segment among end-users.
Key Players: Abbott Laboratories, Boston Scientific Corporation, Medtronic PLC, Biotronik SE & Co. KG, MicroPort Scientific Corporation, Terumo Corporation, Biosensors International Group, Meril Life Science, Stentys SA, Cook Medical Inc., and Lepu Medical Technology. Currently, many manufacturers are outsourcing research to clinical research organizations, which is indirectly boosting the growth of the drug-eluting stents market.
Competitive Analysis: New product development, geographical expansion, collaboration, mergers & acquisitions, and pricing strategies are vital undertakings of players in this space. For instance, in May 2018, MicroPort, a Chinese company, acquired the cardiac rhythm management segment of LivaNova, which has made MicroPort a prominent player in the market. In January 2017, St. Jude Medical, one of the major players in the market, was acquired by Abbott Laboratories for a total of $25 billion. In August 2018, Boston Scientific Corp. signed an agreement to acquire Veniti Inc. Recently, the prices of coronary stents in India have been slashed by around 70%, making it affordable to lower-income people. As a result, Abbott and Boston are withdrawing their most advanced products “Absorb” and “Synergy & Promous Premier”, respectively. This has helped MicroPort to establish its market easily in India with the targeted drug-eluting stents. The technology of MicroPort is proved to be no less than Abbott and other products by market leaders. This is expected to strengthen its market in India.
Benefits: The report provides complete details about the usage and adoption rate of drug-eluting stents in various regions. With that, key stakeholders can know about the major trends, drivers, investments, and vertical player’s initiatives. Moreover, the report provides details about the major challenges that are going to impact on the market growth. Additionally, the report gives the complete details about the key business opportunities to key stakeholders to expand their business and capture the revenue in the specific verticals to analyze before investing or expanding the business in this market.
Key Stakeholders:

Table of Contents
1 Industry Outlook 9
1.1 Industry Overview 9
1.2 Total Addressable Market 11
1.3 Industry Trends 13
2 Report Outline 14
2.1 Report Scope 14
2.2 Report Summary 14
2.3 Research Methodology 15
2.4 Report Assumptions 16
3 Market Snapshot 17
3.1 Market Definition – Infoholic Research 17
3.2 Segmented Addressable Market 17
3.3 Industry Trends 18
3.4 Related Markets 19
3.4.1 Cardiovascular Drugs 19
3.4.1.1 Trends of cardiovascular drugs market 19
3.4.2 Aortic Aneurysm 20
3.4.2.1 Trends of Aortic Aneurysm Market 20
3.4.3 Coronary Stents Market 21
3.4.4 Cardiovascular Diagnostics 21
4 Market Outlook 24
4.1 Reimbursement Scenario 24
4.2 Market Segmentation 27
4.3 Porter 5(Five) Forces 28
4.4 PEST Analysis 29
5 Market Characteristics 30
5.1 Market Dynamics 30
5.1.1 Drivers 30
5.1.1.1 Increasing prevalence of cardiovascular diseases 30
5.1.1.2 Increasing Aging Population 31
5.1.1.3 Growing acceptance for minimally invasive endovascular surgeries 31
5.1.2 Opportunities 32
5.1.2.1 Increase in healthcare spending 32
5.1.2.2 Increase in the number of outpatient procedures 32
5.1.2.3 Market expansion opportunities in emerging nations 32
5.1.3 Restraints 33
5.1.3.1 Stringent regulations for approval process 33
5.1.3.2 Alternative treatment for the drug eluting stents 33
5.1.3.3 Lack of skilled healthcare professionals 33
5.1.3.4 Stringent Regulatory Approval Process 33
5.2 DRO – Impact Analysis 34
5.3 Key Stakeholders 35
6 Types: Market Size and Analysis 36
6.1 Overview 36
6.2 Polymer Based Coating 36
6.3 Polymer free Coating 37
7 Technology: Market Size and Analysis 38
7.1 Overview 38
7.2 Coronary Artery Diseases 39
7.3 Peripheral Artery Disease 42
8 End-users: Market Size and Analysis 43
8.1 Overview 43
8.2 Hospitals and clinics 43
8.3 Ambulatory Surgical Center 45
8.4 Cardiac Centers 45
9 Regions: Market Size and Analysis 46
9.1 Overview 46
9.2 North America 47
9.2.1 Overview 47
9.3 Europe 48
9.3.1 Overview 48
9.4 Asia Pacific 50
9.4.1 Overview 50
9.5 Rest of the World 51
9.5.1 Overview 51
10 Competitive Landscape 53
11 Vendors Profile 56
11.1 Abbott Laboratories 56
11.1.1 Overview 56
11.1.2 Business Unit 59
11.1.3 Geographic Presence 60
11.1.4 Business Focus 60
11.1.5 SWOT Analysis 61
11.1.6 Business Strategy 61
11.2 Boston Scientific Corp 62
11.2.1 Overview 62
11.2.2 Business Units 65
11.2.3 Geographic Presence 66
11.2.4 Business Focus 66
11.2.5 SWOT Analysis 67
11.2.6 Business Strategies 67
11.3 Biotronik, Inc 68
11.3.1 Overview 68
11.3.2 Business Focus 69
11.3.3 SWOT Analysis 70
11.3.4 Business Strategy 70
11.4 Medtronic Plc 71
11.4.1 Overview 71
11.4.2 Business Units 80
11.4.3 Geographic Presence 81
11.4.4 Business Focus 81
11.4.5 SWOT Analysis 82
11.4.6 Business Strategies 82
11.5 Johnson & Johnson 83
11.5.1 Overview 83
11.5.2 Business Units 86
11.5.3 Geographic Revenue 87
11.5.4 Business Focus 88
11.5.5 SWOT Analysis 89
11.5.6 Business Strategies 89
11.6 MicroPort Scientific Corporation 90
11.6.1 Overview 90
11.6.2 Business Units 93
11.6.3 Geographic Presence 95
11.6.4 Business Focus 95
11.6.5 SWOT Analysis 96
11.6.6 Business Strategies 96
12 Vendors Profile 98
12.1 Terumo Corp. 98
12.1.1 Overview 98
12.2 Biosensors International Group 100
12.2.1 Overview 100
12.3 Meril Life Science 101
12.3.1 Overview 101
12.4 STENTYS S.A. 101
12.4.1 Overview 101
12.5 Cook Medical Inc 102
12.5.1 Overview 102
12.6 Lepu Medical Technology Co., Ltd 103
12.6.1 Overview 103
13 Annexure 105
Abbreviations 105

Tables

TABLE 1 TOP ACQUISITIONS IN CARDIOVASCULAR INDUSTRY 13
TABLE 1 DRUG-ELUTING CORONARY STENT WITH ANGIOPLASTY 24
TABLE 2 DRUG-ELUTING CORONARY STENT WITH ATHERECTOMY 24
TABLE 3 DRUG-ELUTING STENT - BYPASS GRAFT REVASCULARIZATION 25
TABLE 4 DRUG-ELUTING CORONARY STENT - CHRONIC TOTAL OCCLUSION REVASCULARIZATION 26
TABLE 5 DRUG ELUTING STENTS MARKET REVENUE BY REGIONS, 2017–2024 ($MILLION) 38
TABLE 6 GLOBAL CORONARY STENTS PIPELINE 39
TABLE 7 DRUG ELUTING STENTS MARKET REVENUE BY REGIONS, 2017–2024 ($MILLION) 47
TABLE 8 OTHER PROMINENT VENDORS OF DRUG ELUTING STENTS MARKET 54
TABLE 2 ABBOTT LABORATORIES: PRODUCT OFFERINGS 56
TABLE 3 ABBOTT LABORATORIES: RECENT DEVELOPMENTS 56
TABLE 9 BOSTON SCIENTIFIC CORP: OFFERINGS 62
TABLE 10 BOSTON SCIENTIFIC CORP: RECENT DEVELOPMENTS 62
TABLE 4 BIOTRONIK INC: PRODUCT OFFERINGS 68
TABLE 5 BIOTRONIK INC: RECENT DEVELOPMENTS 68
TABLE 11 MEDTRONIC PLC: OFFERINGS 71
TABLE 12 MEDTRONIC PLC: RECENT DEVELOPMENTS 71
TABLE 13 JOHNSON & JOHNSON: PRODUCT OFFERINGS 83
TABLE 14 JOHNSON & JOHNSON: RECENT DEVELOPMENTS 84
TABLE 15 MICROPORT SCIENTIFIC: OFFERINGS 90
TABLE 16 MICROPORT SCIENTIFIC CORPORATION: RECENT DEVELOPMENTS 90
TABLE 17 TERUMO CORP.: RECENT DEVELOPMENTS 98
TABLE 18 BIOSENSORS INTERNATIONAL GROUP: RECENT DEVELOPMENTS 101
TABLE 19 STENTYS S.A.: RECENT DEVELOPMENTS 102
TABLE 20 COOK MEDICAL INC: OVERVIEW 103
TABLE 21 COOK MEDICAL INC.: RECENT DEVELOPMENTS 103
TABLE 22 LEPU MEDICAL TECHNOLOGY CO., LTD: OVERVIEW 103
TABLE 23 LEPU MEDICAL TECHNOLOGY CO., LTD.: RECENT DEVELOPMENTS 104


Charts

CHART 1 GLOBAL MEDICAL DEVICES MARKET SEGMENTATION 9
CHART 2 GLOBAL CARDIOVASCULAR DISEASE MARKET 2017 ($BILLION) 12
CHART 3 RESEARCH METHODOLOGY OF GLOBAL DRUG ELUTING STENTS MARKET 15
CHART 4 GLOBAL DRUG ELUTING STENTS MARKET REVENUE, 2017-2024 ($MILLION) 18
CHART 5 SEGMENTATION OF GLOBAL DRUG ELUTING STENTS MARKET 27
CHART 6 PORTER 5 FORCES OF GLOBAL DRUG ELUTING STENTS MARKET 28
CHART 7 PEST ANALYSIS OF DRUG ELUTING STENTS MARKET 29
CHART 8 MARKET DYNAMICS – DRO ANALYSIS 30
CHART 9 WORLD POPULATION AGED 65 YEARS AND ABOVE, 1960-2060 (%) 31
CHART 10 DRO – IMPACT ANALYSIS OF GLOBAL PACEMAKERS MARKET 34
CHART 11 KEY STAKEHOLDERS 35
CHART 12 DRUG ELUTING STENTS MARKET SEGMENT REVENUE BY TYPES, 2017 36
CHART 13 DRUG ELUTING STENTS MARKET SEGMENT SHARE BY TECHNOLOGY, 2017 (%) 38
CHART 14 DRUG ELUTING STENTS MARKET REVENUE IN CORONARY ARTERY DISEASES APPLICATION, 2017-2024 ($MILLION) 41
CHART 15 DRUG ELUTING STENTS MARKET REVENUE IN PERIPHERAL ARTERY DISEASES APPLICATION, 2017-2024 ($MILLION) 42
CHART 16 GLOBAL DRUG ELUTING STENTS MARKET BY END-USER SEGMENTATION, 2017 43
CHART 17 DRUG ELUTING STENTS MARKET BY REGIONAL SEGMENTATION, 2017 (%) 46
CHART 18 DRUG ELUTING STENTS MARKET REVENUE IN NORTH AMERICA, 2017-2024 ($MILLION) 48
CHART 19 DRUG ELUTING STENTS MARKET REVENUE IN EUROPE, 2017-2024 ($MILLION) 49
CHART 20 DURG ELUTING STENTS MARKET REVENUE IN ASIA PACIFIC, 2017-2024 ($MILLION) 51
CHART 21 DRUG ELUTING STENTS MARKET REVENUE IN REST OF THE WORLD, 2017-2024 ($MILLION) 52
CHART 22 ABBOTT LABORATORIES.: OVERVIEW SNAPSHOT 58
CHART 23 ABBOTT LABORATORIES.: BUSINESS UNITS 59
CHART 24 ABBOTT LABORATORIES: GEOGRAPHIC PRESENCE 60
CHART 25 ABBOTT LABORATORIES.: SWOT ANALYSIS 61
CHART 26 BOSTON SCIENTIFIC CORP.: OVERVIEW SNAPSHOT 64
CHART 27 BOSTON SCIENTIFIC CORP.: BUSINESS UNITS 65
CHART 28 BOSTON SCIENTIFIC CORP.: GEOGRAPHIC PRESENCE 66
CHART 29 BOSTON SCIENTIFIC CORP: SWOT ANALYSIS 67
CHART 30 BIOTRONIK INC.: SWOT ANALYSIS 70
CHART 31 MEDTRONIC PLC: OVERVIEW SNAPSHOT 78
CHART 32 MEDTRONIC PLC: BUSINESS UNITS 80
CHART 33 MEDTRONIC PLC: GEOGRAPHIC PRESENCE 81
CHART 34 MEDTRONIC PLC: SWOT ANALYSIS 82
CHART 35 JOHNSON & JOHNSON: OVERVIEW SNAPSHOT 85
CHART 36 JOHNSON & JOHNSON: BUSINESS UNITS 86
CHART 37 JOHNSON & JOHNSON: GEOGRAPHIC REVENUE 87
CHART 38 JOHNSON & JOHNSON: SWOT ANALYSIS 89
CHART 39 MICROPORT SCIENTIFIC CORPORATION: OVERVIEW SNAPSHOT 93
CHART 40 MICROPORT SCIENTIFIC CORPORATION: BUSINESS UNITS 93
CHART 41 MICROPORT SCIENTIFIC CORPORATION: GEOGRAPHIC PRESENCE 95
CHART 42 MICROPORT SCIENTIFIC CORPORATION: SWOT ANALYSIS 96

None

Abbott Laboratories
Boston Scientific Corporation
Medtronic plc
Johnson and Johnson
MicroPort Scientific Corporation
Biotronik Inc

Custom Research

Looking for more specific research study and analysis? Contact our Custom Research Team

Write to Custom Research Team